Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%

Aurinia Pharmaceuticals Inc. AUPH was a big mover last session, as its shares rose almost 6% on the day. The move came after the company announced that it has selected Worldwide Clinical Trials as its Clinical Research Organization for the AURORA Phase 3 study of volcosporin for the treatment of active lupus nephritis. This led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 56.3% in the past one-month time frame.

Over the last 30 days, the company witnessed three positive estimate revisions. The Zacks Consensus Estimate also moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

Aurinia Pharmaceuticals currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Another favorably placed stock in the Medical – Drugs space is FibroGen, Inc. FGEN, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is AUPH going up? Or down? Predict to see what others think: Up or Down

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research